Ray Dalio Neogenomics Inc Transaction History
Bridgewater Associates, LP
- $21.1 Billion
- Q4 2024
A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Neogenomics Inc stock. As of the latest transaction made, Bridgewater Associates, LP holds 14,397 shares of NEO stock, worth $141,666. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,397
Previous 50,354
71.41%
Holding current value
$141,666
Previous $742,000
68.06%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding NEO
# of Institutions
282Shares Held
124MCall Options Held
751KPut Options Held
107K-
Black Rock Inc. New York, NY19.7MShares$194 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.2MShares$140 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.53MShares$64.2 Million0.07% of portfolio
-
Janus Henderson Group PLC London, X06.17MShares$60.7 Million0.05% of portfolio
-
Brown Advisory Inc6.16MShares$60.6 Million0.13% of portfolio
About NEOGENOMICS INC
- Ticker NEO
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 125,796,000
- Market Cap $1.24B
- Description
- NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytoge...